David Stump
Vermögen: 263 676 $ am 31.05.2026
Vermögen: 263 676 $ am 31.05.2026
David C.
Stump is an Independent Director at REGENXBIO, Inc. since 2015 and at MacroGenics, Inc. since 2013.
Dr. Stump serves as a Trustee at Earlham College.
Former roles include Independent Director at Dendreon Corp.
from 2011 to 2015, Independent Director at Sunesis Pharmaceuticals, Inc. from 2006 to 2021, Independent Director at Portola Pharmaceuticals LLC from 2015 to 2020, Vice President-Clinical Research at Genentech, Inc. from 1989 to 1999, Executive Vice President-Research & Development at Human Genome Sciences, Inc. from 2007 to 2012, Associate Professor at the University of Vermont, and Trustee at Adventist HealthCare, Inc. from 2000 to 2012.
Education includes undergraduate studies at Earlham College and a doctorate from Indiana University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
REGENXBIO, INC. 0,06 % | 29.05.2026 | 28.861 ( 0,06 % ) | 202 316 $ | 31.05.2026 |
MACROGENICS, INC. 0,02 % | 19.05.2026 | 14.750 ( 0,02 % ) | 61 360 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| MACROGENICS, INC. | Direktor/Vorstandsmitglied | 19.09.2013 |
| REGENXBIO INC. | Direktor/Vorstandsmitglied | 15.10.2015 |
Earlham College
Earlham College Other Consumer ServicesConsumer Services Functions as a College/University | Direktor/Vorstandsmitglied | 22.02.2010 |
| Unternehmen | Position | Ende |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 24.02.2021 |
| PORTOLA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 01.07.2020 |
| DENDREON CORPORATION | Direktor/Vorstandsmitglied | 10.06.2015 |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Provides pharmaceutical and diagnostic products | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2012 |
Adventist HealthCare, Inc.
Adventist HealthCare, Inc. Medical/Nursing ServicesHealth Services Provides health care services | Direktor/Vorstandsmitglied | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 11 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Provides pharmaceutical and diagnostic products | Health Technology |
Dendreon Corp.
Dendreon Corp. Medical SpecialtiesHealth Technology Discovers, develops and commercializes novel products for the treatment of cancer | Health Technology |
Sunesis Pharmaceuticals, Inc.
Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops oncology therapeutics for treatment of solid and hematologic cancers | Health Technology |
Portola Pharmaceuticals LLC
Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in development and commercialization of novel therapeutics | Health Technology |
REGENXBIO, Inc.
REGENXBIO, Inc. Pharmaceuticals: MajorHealth Technology Develops gene therapy | Health Technology |
MacroGenics, Inc.
MacroGenics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes antibody-based therapeutics for the treatment of cancer | Health Technology |
Earlham College
Earlham College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Indiana University
Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Vermont
University of Vermont Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adventist HealthCare, Inc.
Adventist HealthCare, Inc. Medical/Nursing ServicesHealth Services Provides health care services | Health Services |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen